Knowledge of Coumadin Use in Atrial Fibrillation Potients by Viau, Krista Skye
Utah State University 
DigitalCommons@USU 
Undergraduate Honors Capstone Projects Honors Program 
5-2009 
Knowledge of Coumadin Use in Atrial Fibrillation Potients 
Krista Skye Viau 
Utah State University 
Follow this and additional works at: https://digitalcommons.usu.edu/honors 
 Part of the Agricultural and Resource Economics Commons 
Recommended Citation 
Viau, Krista Skye, "Knowledge of Coumadin Use in Atrial Fibrillation Potients" (2009). Undergraduate 
Honors Capstone Projects. 19. 
https://digitalcommons.usu.edu/honors/19 
This Thesis is brought to you for free and open access by 
the Honors Program at DigitalCommons@USU. It has 
been accepted for inclusion in Undergraduate Honors 
Capstone Projects by an authorized administrator of 
DigitalCommons@USU. For more information, please 
contact digitalcommons@usu.edu. 
KNOWLEDGE OF COUMADIN USE IN ATRIAL 
FIBRILLATION PATIENTS 
 
 
 
by 
 
 
Krista S. Viau 
 
 
 
 
Thesis submitted in partial fulfillment  
of the requirements for the degree 
 
of 
 
 
DEPARTMENTAL HONORS 
 
in 
 
Dietetics 
in the Department of Nutrition and Food Sciences  
 
 
 
Approved: 
 
 
              
Thesis/Project Advisor     Departmental Honors Advisor 
Megan Bunch, RD, MS     Janet Anderson, RD, MS 
 
 
      
Director of Honors Program 
Dr. Christie Fox 
 
 
 
UTAH STATE UNIVERSITY 
Logan, UT 
 
Spring Semester 2009  
Title of Contents 
Abstract 2
 
Introduction 3
 
Research Objective 4
 
Review of Literature 5
 
Methods 11
 
Results 14
 
Discussion 15
 
Conclusion 17
 
References 18
 
Author Biography 20
 
Appendix 1 21
 
2 
Abstract
 
Background: Atrial fibrillation (AF) is the most common observed arrhythmia in clinical 
practice. Over the next decades, the number of people affected by AF is estimated to be 
anywhere from 5.6 to over 12 million. In patients with AF, thromboembolism is a central 
concern, as it can lead to stroke with significant morbidity and mortality. Coumadin 
anticoagulation has been shown to significantly reduce stroke risk, particularly in patients with 
other risks, such as hypertension, diabetes, prior stroke, or heart failure. Although Coumadin is 
effective in reducing stroke, its chronic use requires frequent international normalized ratio 
(INR)/protime monitoring. This is necessary because nutritional status, compliance, and drug 
interactions can lead to under- or over-coagulation. There can be numerous interactions with 
food and medications in patients using Coumadin. In addition, Coumadin carries with it the 
major concern of intracranial bleeding. Consequently, identifying knowledge deficits related to 
Coumadin use is critical to improving patient outcomes. 
Methods: This study took place at Intermountain Medical Center, Murray, Utah, in collaboration 
with Utah State University, Logan, Utah. Patients with known AF, who were receiving treatment 
from the Utah Heart Clinic (n=75), were asked to complete a one-time questionnaire. The data 
thus obtained was analyzed to identify any knowledge deficits related to Coumadin use. 
Results: It was found that 90.7 percent of the sample had at least one stroke risk factor. 
Descriptive data indicated 21.3 percent of all participants reported consuming grapefruit and/or 
grapefruit juice and were unaware of the interaction with Coumadin. 
Conclusions: This is of great clinical significance as lack of knowledge increased the risk for 
thromboembolism and intracranial bleeding. The results may be skewed due to the common 
knowledge of grapefruit-drug interactions. We conclude that better strategies need to be devised 
to effectively educate AF patients on Coumadin to improve treatment outcomes in the future. 
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Research Objective 
Patient outcomes can be improved through intervention and education pertaining to 
nutrition, compliance, and understanding ofdrug interactions. Variability in dietary 
consumption ofvitamin K destabilizes anticoagulation control ofCoumadin. Consumption of 
grapefruit alters the metabolism of the drug and can lead to intracranial bleeding. Many 
prescription drugs, over-the-counter medications, and herbal products/supplements interact with 
the metabolism ofCoumadin and can lead to over- or under-anticoagulation. Noncompliance 
with Coumadin has been estimated at 21 percent in the elderly, who often perceived that they 
were more compliant than they actually were. Patient education communicating these ideas is 
widely available and frequently used for patients with cardiovascular disease but is neither 
widely available nor frequently used for patients taking Coumadin. The objective ofthis study is 
to assess the understanding of the AF population related to their role in reducing the risks 
associated with Coumadin and the effects ofproper understanding on stroke risk. 
4 
Introduction
 
Atrial fibrillation (AF) is the most commonly observed arrhythmia in clinical practice. 
Over the next decades, the number of people affected by AF is estimated to be anywhere from 
5.6 to over 12 million (1,2). While age is a key risk factor for AF, other population 
demographics will also likely contribute to the increased AF prevalence. Both the Framingham 
study and a cohort from Olmsted County, Minnesota have shown age-adjusted increases in the 
prevalence and incidence of atrial fibrillation from the 1960's to 1989 (3-4). The epidemiologic 
changes of AF are a global phenomena with incidence and prevalence data from the Netherlands 
similar to the US. AF admissions are also on the rise in China (5-6). 
In patients with AF, thromboembolism is a central concern as it can lead to stroke with 
high rates of morbidity and mortality. Coumadin anticoagulation has been shown to significantly 
reduce stroke risk, particularly in those with other risk factors of stroke such as hypertension, 
diabetes, prior stroke, or heart failure (7-11). Although Coumadin is effective in reducing stroke, 
its chronic use requires frequent INR/protime monitoring. Nutritional status, hepatic function, 
intestinal absorption, compliance, and genetic polymorphisms are factors that can lead to under­
or overanticoagulation with long-term use of Coumadin. There are also numerous dietary and 
medication interactions and the major concern of intracranial bleeding, all of which could lead to 
stroke (12). 
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Review of Literature 
It is generally accepted that certain foods may interact with the pharmacokinetics of 
certain medications (13). In 1991, researchers inadvertently discovered the drug-grapefruit juice 
interaction that enhances the area under the concentration time curve (AUC) and the maximum 
plasma concentration (Cmax) of orally administered drugs (13). Drugs with lower oral 
bioavailability are affected to a greater degree. This interaction has been reported with 40 
pharmaceutical products, including the vitamin K antagonist, Coumadin (13). 
Subsequent investigations of this interaction indicated that grapefruit juice acts by 
inhibiting cytochrome P450 3A4 (CYP3A4) expression (14). Cytochrome 450 (CYP450) 
enzymes are in a class of over 50 enzymes. Six of those are responsible for metabolizing 90 
percent of drugs, with the two most significant enzymes being CYP3A4 and CYP2D6 (15). 
Drug metabolism may be the result of one or several CYP450 enzymes. For example, 
Coumadin is metabolized by CYPIA2, CYP2D6, and CYP3A4 (15). Drugs that interact with 
CYP450 enzymes are known as either inhibitors or inducers. Inhibitors block the activity of one 
or more CYP450 enzymes, amplifying the effect of the drug (15). A drug can both inhibit an 
enzyme and be metabolized by the same enzyme. Conversely, inducers enhance the synthesis of 
CYP450 enzymes, thus reducing the drug's effect. Adverse effects are more common if the drug 
has a narrow safety range and if it is metabolized by only one enzyme (15). 
Grapefruit juice inhibits CYP3A4 synthesis and accelerates CYP3A4 degradation, which 
indicates the process is mechanism-based opposed to competitive (13). Mechanism-based 
inhibition involves an inhibitor being metabolically activated by an enzyme and then irreversibly 
inactivating that same enzyme. This means that the return of enzyme activity wiIl require de 
novo enzyme synthesis and prolong the effect of the inhibitor (13). For this reason, the effects of 
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grapefruit juice typically last 24 hours (14). Drug-grapefruit juice interactions, therefore, cannot 
be fully avoided by taking them at a different time (16). 
Drug-grapefruit juice interactions are unique in that while apical enterocytes and 
hepatocytes both contain CYP3A4, ingestion of normal amounts of grapefruit juice only appears 
to alter intestinal CYP3A4 expression (14). Studies demonstrated a 62 percent reduction in 
intestinal CYP3A4 protein content after consuming grapefruit juice over 5 days (14). However, 
repeated dosing of large amounts of grapefruit juice over several days can also inhibit hepatic 
CYP3A4 synthesis (16). The content of intestinal and hepatic CYP3A4 can vary tenfold among 
individuals and appears to be regulated independently of the other. Therefore, the magnitude of 
the interaction is highly variable (14). 
Identification of the active ingredients in grapefruit juice is important, as it would enable 
researchers to evaluate its effect on CYP3A4 with other foods. In addition, the active ingredients 
may be used in commercial products to produce higher drug bioavailability (14). Several 
components of grapefruit juice have been proposed as the cause of this interaction, including 
flavonoids and furanocoumarins. 
The most prevalent flavonoid in grapefruit juice is naringin (14). Naringin is in high 
concentration in grapefruit juice and absent from orange juice, which does not interact with 
Coumadin. While naringin has potential to inhibit CYP3A4 synthesis, it is less potent than its 
aglycone, naringenin (14). Naringenin is typically not present in grapefruit juice, but studies 
demonstrated renal excretion of naringenin conjugates after administration of grapefruit juice, 
suggesting in vivo naringenin formation. However, ingestion of commercial pure naringin in the 
same amounts as grapefruit juice produced little to no effect (14). 
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More recent studies concluded that furanocoumarins are the major CYP3A4 inhibitors in 
grapefruit juice. Bergamottin and 6' ,7'-dihydroxybergamottin (DHB) are the two most abundant 
furanocoumarins in grapefruit juice (17). In order to accurately evaluate their impact on 
CYP3A4 inhibition, a furanocoumarins-free (FC-free) formula was created. The recorded results 
reported the ADC of grapefruit juice to be 30 to 370 percent higher than that of the FC-free 
grapefruit juice (17). The FC-free formula behaved in a similar manner to orange juice. It 
produced some effects, but to a much lesser degree (17). While furanocoumarins appear to be 
the active ingredient in grapefruit juice, no individual furanocoumarin is able to completely 
reproduce the inhibitory effect of whole juice. It is not possible to determine which 
furanocoumarin contributes the most to the grapefruit juice-drug interaction (17). 
There have been recent attempts to remove FCs from grapefruit juice, which include 
chemical, physical, and microbiological methods. One of these methods involves the use of 
autoclaved fungus to absorb and remove FCs, specifically M. esculenta (18). M. esculenta 
efficiently absorbed all non-polar FCs in grapefruit juice. However, polar FCs were not 
absorbed, which caused 40% of the CYP3A4 inhibition to remain (18). The binding of FCs to 
the fungi is believed to be due to passive interaction. This interaction was successful in 
reducing the potency of the inhibitory effect of grapefruit juice on CYP3A4 (18). 
The vitamin K antagonist Coumadin has multiple food-drug and drug-drug interactions, 
including grapefruit juice. Coumadin is the most extensively used oral anticoagulant worldwide. 
It is indicated to prevent thromboembolism, myocardial infarction, and stroke in patients with 
atrial fibrillation (AF) and prosthetic heart valves (19). AF increases the risk of stroke five-fold. 
Coumadin reduces the risk of AF-related stroke by 64 to 70 percent (20). 
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Coumadin acts by inhibiting the vitamin K-dependent coagulation factors II, VII, IX, and 
X. The drug is promptly absorbed and its concentration peaks around 4 hours (19). Coumadin is 
eliminated through metabolism by hepatic CYP2C9. There are several variations in the gene that 
encodes CYP2C9 among different ethnic groups. These variants are associated with an increase 
in negative clinical outcomes, including over- and under-anticoagulation, both of which can lead 
to stroke (19). Inadequate amounts of Coumadin can increase the risk for a thromboembolism 
leading to an ischemic stroke. An abundance of Coumadin can increase the risk of intracranial 
bleeding, which could cause a hemorrhagic stroke (19). 
The dose-response to Coumadin has a large range due to intrinsic genetic factors, 
comorbid diseases, other medications, and dietary factors, all of which can alter drug 
metabolism. While grapefruit juice can significantly amplify the effects of Coumadin, it does 
not appear to alter the anticoagulant response (19). Due to the wide dose-response of Coumadin 
and the wide dose-response of grapefruit juice, medical professionals cannot safely recommend a 
specific amount of grapefruit juice that one could ingest while taking Coumadin. 
The current patient education methods utilized in health care facilities may not be 
adequate to convey the importance of adherence to the prescription and the seriousness and 
understanding of food-drug interactions, especially concerning grapefruit juice. Adverse effects 
of Coumadin are common with non-adherence. Poor adherence is estimated to cause 5 percent 
of all hospital admissions, which accrue 8 billion dollars in cost every year (20). Anticoagulants 
are believed to be the leading cause of preventable adverse drug-related events among the 
elderly. 
The INR Adherence and Genetics (IN-RANGE) study demonstrated that over 40 percent 
of participants were less than 80 percent adherent with their Coumadin prescription (20). 
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Overall non-adherence was significantly associated with underanticoagulation and altered INR 
levels. No differences were found when examining compliance with initiation versus 
maintenance of Coumadin. These findings are significant as even moderate fluctuations in INR 
are associated with increased risk of thromboembolism, additional visits, increased need for dose 
changes, and a higher potential for dosing errors (20). 
The latest results from the IN-RANGE study lend support to the hypothesis of poor 
compliance among those taking Coumadin. Non-adherence was reported in 21 percent of the 
days observed, with individual numbers ranging from 0.9 to 79 percent (21). Increased non­
adherence was significantly associated with those with education beyond a high school diploma, 
those with active employment, and those with lower cognitive functioning. 
Poor adherence in educated populations may be due to more independent decision­
making or decreased trust in physicians (21). The negative association with employment and 
medication adherence is consistent with other studies and other disease settings. While the 
underlying relationship is not definite, it is hypothesized that employment may represent several 
factors, which take priority over consistent pill taking (21). Lower cognitive function was 
associated with non-adherence, but there was no association with depressive symptoms. Patient 
adherence to Coumadin appears to be related to factors involving time, memory, and mental 
health functioning (21). 
Health literacy may also playa role in patient compliance and understanding. Previous 
studies demonstrated decreased patient knowledge and lack of Coumadin education are 
associated with reduced anticoagulant control and increased risk of hemorrhagic events (22). 
Health education brochures are typically written at a ninth-grade level or higher. A recent study 
demonstrated that out of 179 interviewed patients, 33.5 percent reported having no more than an 
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eighth-grade level education (22). Limited health literacy was prevalent in 60.9 percent of the 
multi-cultural population and was more likely to occur in those that were older, female, non­
white, and have less than a high school education. 
Limited health literacy increased the amount of incorrect answers concerning Coumadin 
related knowledge (22). The patients taking Coumadin for atrial fibrillation were more likely to 
report that their physician had not explained that they had atrial fibrillation (60 percent vs. 
9.7percent) and were less likely to understand that it increased their risk of stroke (42 percent vs. 
70 percent). Despite these differences, limited health literacy was not significantly associated 
with poor INR control (22). 
Coumadin is a beneficial but potentially hazardous medication. Appropriate education 
has a profound impact on patient knowledge of Coumadin use, INR control, and prevalence of 
drug-related complications. 
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Methods
 
This study was conducted at Intennountain Medical Center (Murray, Utah) in 
collaboration with Utah State University (Logan, Utah). Patients with known AF who were 
receiving treatment from the Utah Heart Clinic (n=75) and were currently taking Coumadin were 
asked to complete a one-time questionnaire of 52 questions. The questionnaire was completed 
under the supervision of a registered dietitian or student dietitian. Data collected was analyzed to 
assess the descriptive characteristics of the data and to identifY any knowledge deficits related to 
Coumadin use and was stratified based on stroke risk versus non-stroke risk. This study was 
approved by the Institutional Review Board at Utah State University (protocol #2187). 
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Results
 
The mean age of the patient population was 69.2 (n=75). The data was stratified by 
gender to assess differences between male and female. The patients were categorized according 
to stroke risk, based on the CHADS2 Score. The CHADS2 score is used to estimate risk of stroke 
in AF patients. 
Sixty-eight of the patients had at least one risk factor for stroke (see Table 1). The seven 
remaining patients with no stroke risk factors were taking Coumadin because they had recently 
undergone a cardiac ablation. 
Hypertension was the most common stroke risk factor (58.7 percent of the population). 
Age> 75 years was the second most common, followed by heart failure. 
Table 1. Stroke Risk Characteristics 
Item M+F M F 
n(%) n(%) n(%) 
n 75 47 28 
Age 69.2 66.7 72.3 
Stroke Risk 
1. Hypertension 44(58.7) 28(59.6) 16(57.1) 
2. Heart failure 25(33.3) 14(29.8) 11(39.3) 
3. Age >75 26(34.7) 12(25.5) 14(50.0) 
4. Diabetes 12(16.0) 7(14.9) 5(17.9) 
5. TIA 19(25.3) 11(23.4) 8(28.6) 
7. TIA on Coumadin 6(8.0) 3(6.6) 3(10.7) 
Table 2 represents the patient population (n=16) who reported having consumed 
grapefruit or grapefruit juice and were not aware that grapefruit interacts with Coumadin. 
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Possible responses to the grapefruit or grapefruit juice consumption question ranged from "every 
day" to "less than once a month." Table 2 reveals that 21.3 percent of those that consumed 
grapefruit or grapefruit juice were unaware of this interaction. 
Table 2. Those Who Were Not Aware Of Grapefruit Interaction With Coumadin 
Item M+F M F 
n(%) n(%) n(%) 
Grapefruit 16(21.3) 10(21.3) 6(21.4) 
Table 3 presents the data from the grapefruit or grapefruit consumption question only 
with respect to members of the population having stroke risk (n=68). Surprisingly, there was no 
difference in the proportion (21.3 percent) that were not aware of the grapefruit interaction with 
Coumadin. 
Table 3. Those At Stroke Risk Who Were Not Aware Of Grapefruit Interaction With 
Coumadin 
Item M+F M F 
n(%) n(%) n(%) 
Grapefruit 16(21.3) 10(21.3) 6(21.4) 
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Discussion 
Seventy-five patients participated in this study. Of these, 68 had at least one stroke risk 
factor, which included hypertension, heart failure, age over 75 years, diabetes, and prior stroke. 
The study demonstrated that 21.3 percent of those who consumed grapefruit or grapefruit juice 
were not aware of its interaction with Coumadin. While this study was the first to assess patient 
knowledge of specific drug-nutrient and drug-drug interactions, our results are similar with other 
research assessing overall patient understanding of Coumadin (23). 
A recent study demonstrated that 83 percent of patients were aware that too little 
Coumadin could lead to an ischemic stroke, but only 21 percent were aware that too much could 
lead to a hemorrhagic stroke (23). Thirteen percent of patients did not know that Coumadin 
could cause bruising or internal bleeding. Patient beliefs also included 12 percent claiming they 
were able to determine if the Coumadin was at the right level by how they felt and 13 percent 
stating that missing a lab appointment was not that important (23). 
Appropriate education tools are essential to overcome these barriers. There has been 
debate about the effectiveness of presenting statistics in educational materials compared with 
narratives (23). A growing amount of literature suggests that even well educated patients 
struggle comprehending quantitative information. Narratives may be more engaging, 
memorable, and realistic than statistics, but may induce inaccurate beliefs or lead to non-optimal 
decision-making (23). 
Patients viewing a video education tool with evidence presented in a narrative format 
showed greater knowledge gains than those that received statistical evidence (p=O.OO6). There 
were no significant differences in the narrative version compared to the video with narrative plus 
statistical evidence (23). Narrative evidence may be more effective in Coumadin education. The 
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videos used in this study did have a positive impact; however, they did not correct knowledge 
gaps, reduce incorrect beliefs, or improve non-adherence. Patients may benefit from periodic 
Coumadin education. Clinicians should not assume that those who have been taking Coumadin 
for months or years have adequate knowledge of its drug-nutrient and drug-drug 
interactions (23). 
The results of this study may have been skewed by common knowledge that grapefruit 
interacts with most medications, especially many cardiovascular and hypertensive agents. With 
that in mind while completing the questionnaire, the participants may have merely guessed, 
rather than answering based on their specific knowledge, that Coumadin interacts with 
grapefruit. 
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Conclusion 
This is the first study to assess and compare the association of various risk factors with 
Coumadin knowledge. Stroke risk patients (n=68) had limited knowledge related to Coumadin 
use. As most patients had at least one stroke risk factor, comparison of stroke risk patients and 
their non-stroke counterparts was not possible. AF patients did not ask professionals about 
Coumadin interactions. Specifically, 21.3 percent of those consuming grapefruit or grapefruit 
juice did not ask a professional if the product interacts with Coumadin. Only 63.9 percent of 
participants were knowledgeable about at least one dietary influence on Coumadin metabolism. 
Lack ofpatient knowledge may increase the risk for thromboembolism and intracranial 
bleeding in patients taking Coumadin. Dietary factors, drug compliance, and interactions with 
Coumadin can be positively influenced through intervention and education. Better strategies 
need to be devised to effectively educate AF patients on Coumadin to improve treatment 
outcomes in the future. Further data analysis will take place to identify specific correlations in 
order to improve patient education in the future. 
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Appendix 1
 
Survey Instrument
 
21 
Age _ 
Please circle: 
Gender 
Male 
Female 
Education Level 
Less than the 8th Grade 
8-12th Grade 
High School Graduate 
College Graduate 
Advanced Degree 
Stroke Risk Factors 
1. High blood pressure: YeslNo 
2. Heart failure: YeslNo 
3. Age greater than 75 years: YeslNo 
4. Diabetes: YeslNo 
5. Prior stroke or mini-stroke (TIA): YeslNo 
7. Prior stroke or mini-stroke when on Coumadin: YeslNo 
If you had a stroke on Coumadin, was your blood level: 
a. Too low 
b. Normal 
c. Too high 
d. Not sure 
1 
Other Cardiac Problems 
1. Have you had a prior heart attack: YeslNo 
2. Have you had a stent or bypass surgery: Yes/No 
3. Do you have any problems with your heart valves: Yes/No 
If yes, was the problem: 
a. Narrow 
b. Leaky 
c. Not sure 
4. Have you had surgery for your heart valves: YeslNo 
Please answer the following questions: 
1. Have you ever experienced bleeding in your urine or stools? YeslNo 
2. Have you ever received a blood transfusion because of bleeding? Yes/No 
3. Have you fallen in the past year? Yes/No 
4. If you have fallen in the past year, how many times? __ 
5. How long have you been on Coumadin? 
a. Less than 1 year 
b. 1 year - 5 years 
c. 5 years - 10 years 
d. Greater than 10 years 
e. Not sure 
2 
6. Do you take your Coumadin as prescribed by your doctor? YeslNo 
7. Do you ever skip your Coumadin dose? YeslNo 
8. Do you ever double up your Coumadin dose? YeslNo 
9. Do you ever not refill your Coumadin because of cost? YeslNo 
10. What is the most common reason why you may not take your Coumadin dose? 
a. Cost 
b. Forgetting 
c. Mixing up medications 
d. Lack ofdesire 
e. Illness 
f. None of the above 
11. Have you gained weight after starting Coumadin? YeslNo 
12. If yes, approximately how much weight have you gained? __ 
13. If yes, why do you think you gained the weight? (Circle all that apply) 
a. Changed diet and avoided vegetables 
b. Exercised less 
c. Ate more at each meal 
d. Craved new foods that were less healthy 
3 
14. Have you lost weight after starting Coumadin? Yes/No 
15. If yes, approximately how much weight have you lost? __ 
16. If yes, why do you think you lost the weight? (Circle all that apply) 
a. Changed diet and avoided many foods 
b. Illness 
c. Ate less at each meal 
d. Stopped drinking alcohol 
17. What is considered a normal INR (blood Coumadin level)? 
a. Less than 1
 
b.2-3
 
c.4-5
 
d. Greater than 5 
e. Not sure 
18. Do you know what your current INR (blood Coumadin level) is? Yes/No 
19. Approximately how often do you get your INR (blood Coumadin level) checked? 
a. Once a week 
b. Twice a month 
c. Once a month 
d. Twice a year 
e. Once a year 
d. Never 
f. Not sure 
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20. Do you ever not get your INR (blood Coumadin level) checked because of cost? 
YeslNo 
21. Are you aware that your other medications can interact with Coumadin? YeslNo 
22. Do you ask your pharmacist before starting a new medication if it interacts with 
Coumadin? Yes/No 
23. Do you ever take over-the-counter pain medications? YeslN0 
24. If yes, which ones? (Circle all that apply)
 
Excedrin® Tylenol® (Acetaminophen) Aleve® (Naproxen)
 
Advil® (Ibuprofen) Motrin® (Ibuprofen) Aspirin
 
25. Do you ask your doctor before using over-the-counter pain medications? YeslNo
 
26. Do you ever take over-the-counter stomach remedies? Yes/No
 
27. If yes, which ones? (Circle all that apply)
 
Tagamet HB® (Cimetidine) Pepto Bismol® (Bismuth Subsalicyclate)
 
Laxatives Stool Softeners
 
Alka-Seltzer®
 
28. Do you ask your doctor before using over-the-counter stomach remedies? Yes/No
 
29. Do you take vitamin supplements? Yes/No 
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30. If yes, which ones (Circle all that apply) 
Multivitamin (Dose: ) 
Vitamin A (Dose: ) 
Vitamin E (Dose: ) 
Vitamin D (Dose: ) 
Vitamin C (Dose: ) 
31. Are you aware that vitamin supplements can interact with Coumadin? Yes/No 
32. Do you ask your doctor before using a vitamin supplement if it interacts with 
Coumadin? Yes/No 
33. Do you think getting enough Vitamin K is important? 
a. Yes
 
b.No
 
c. Not sure 
34. What do you think Vitamin K does for us? (Circle all that apply) 
a. Improves eye sight 
b. Strengthens bones 
c. Improves the texture and softness of skin 
d. Helps to form clots 
e. It is an anti-oxidant to help the body 
35. Do you take any herbal or natural medications or supplements? Yes/]\To 
6 
36. If yes, which ones? (Circle all that apply) 
Garlic Ginger Glucosarnine 
Ginko Biloba CoEnzyme Q10 Green Tea 
St. John's Wort Flaxseed Melatonin 
Papaya Extract Ginseng Soy Protein Products 
Fish oil supplements that contain EPA or DHA 
37. Are you aware that natural medications or supplements can interact with Coumadin? 
YeslNo 
38. Do you ask your doctor before using a natural medication or supplement if it interacts 
with Coumadin? YeslNo 
39. Do you know how to interpret a supplement facts label on natural medications or 
supplements? YeslNo 
40. How often do you drink alcoholic beverages? 
a. Every day 
b. 4-6 days a week 
c. 2-3 days a week 
d. Once a week 
e. 2-3 times a month 
d. Once a month 
e. Less than once a month 
f. Never 
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41. How often do use tobacco products? 
a. Every day 
b. 4-6 days a week 
c. 2-3 days a week 
d. Once a week 
e. 2-3 times a month 
d. Once a month 
e. Less than once a month 
f. Never 
42. Can changing your diet change your Coumadin dose? 
a. Yes
 
b.No
 
c. Not sure 
43. How often do drink grapefruit juice or eat grapefruit? 
a. Every day 
b. 4-6 days a week 
c. 2-3 days a week 
d. Once a week 
e. 2-3 times a month 
d. Once a month 
e. Less than once a month 
f. Never 
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44. Are you aware that grapefruit and grapefruit juice interact with Coumadin? 
a. Yes
 
b.No
 
c. Not sure 
45. Are you aware that you get Vitamin K from the foods you eat? 
a. Yes
 
b.No
 
c. Not sure 
46. How much Vitamin K do the following foods contain? Please circle the amount: 
Cooked broccoli 
(l cup) 
0-9 meg 10-29 meg 30-89 meg 99-1200 meg 
Vegetable Oil (l 
Tbsp) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Canned tuna in 
oil (3 oz) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Iceberg lettuce (l 
cup) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Cooked spinach 
(l cup) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Coleslaw (3/4 
cup) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Red grapes (l 
cup) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Green leaf 
lettuce (1 cup) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Walnuts (14 
halves) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Grapefruit juice 
(l cup) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
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Red wine (3.5 f1 
oz) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Olive Oil (1 
tbsp) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Cooked 
asparagus (4 
spears) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Raw celery (l 
stalk) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Vanilla ice 
cream (1/2 cup) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Avocado (3 oz) 0-9 meg 10-24 meg 25-99 meg 100-499 meg 
75% lean ground 
beef(30z) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Roasted chicken 
(l drumstick) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Raw pineapple 
(l cup) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Cooked salmon 
(1/2 fillet) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Swiss cheese (1 
oz) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
2% milk (1 cup) 0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Hard-boiled egg 
(llarge) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
Chunky peanut 
butter (l Tbsp) 
0-9 meg 10-24 meg 25-99 meg 100-499 meg 
47. Do you know how to interpret a nutrition facts label on food products? YeslNo 
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48. How many meals do you eat each day? 
a. One 
b. Two 
c. Three 
d. Four 
e. Five 
f. Less than one 
g. More than 5 
49. How many meals do you eat each day with Vitamin K? 
a.One 
b. Two 
c. Three 
d. Four 
e. Five 
f. Less than one 
g. More than 5 
h. Not sure 
50. Is it important to watch how much Vitamin K you get each day when you are on 
Coumadin? 
a. Yes
 
b.No
 
c. Not sure 
51. Do you believe that taking Coumadin negatively influences your quality of life? 
Yes/No 
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52. If yes, why do you think Coumadin negatively influences your quality of life? (Circle 
all that apply) 
a. Frequent blood draws 
b. Don't get to eat your favorite foods 
c. Diet is too restrictive 
d. No longer drink alcohol or only occasionally 
e. Worry about bleeding 
f. Feel unwell or experience side effects on the medication 
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